

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/028458 A2

(51) International Patent Classification:

C07D 401/14 (2006.01) A61P 25/18 (2006.01)
A61P 25/00 (2006.01) A61P 25/28 (2006.01)
A61P 25/04 (2006.01) A61K 31/454 (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:

PCT/EP2023/071591

(22) International Filing Date:

03 August 2023 (03.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2211399.7	04 August 2022 (04.08.2022)	GB
2305444.8	13 April 2023 (13.04.2023)	GB
2309615.9	26 June 2023 (26.06.2023)	GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**

[GB/GB]; Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(72) Inventors: **BROWN, Giles Albert**; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

MC GEE, Paul; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).
CANSFIELD, Julie; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).
PICKWORTH, Mark; c/o Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge Cambridgeshire CB21 6DG (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: **MUSCARINIC RECEPTOR AGONISTS**

(57) **Abstract:** This invention relates to compounds and salts thereof that are muscarinic receptor agonists and which are useful in the treatment of muscarinic receptor mediated diseases. Also provided are crystalline forms of the compounds and salts thereof; pharmaceutical compositions containing the compounds and salts thereof, or crystalline forms thereof; therapeutic uses of the compounds and salts thereof, or crystalline forms thereof; methods of synthesis thereof; and intermediates useful in said methods of synthesis.



WO 2024/028458 A2